Meet David, living with CLL with genetic aberrations
About David
- 65 years old
- Lymphocytosis incidentally noted
on routine complete blood count
Medical history
- No previous treatment for CLL
Physical examination
- 1-cm cervical node, no palpable spleen
Laboratory results
- White blood cell: 45,000 /μL; 79% lymphocytes
- Haemoglobin: 13 g/dL
- Platelets: 140,000 /µL
- Beta2-microglobulin: 3.0 mg/L (mildly elevated)
- Flow cytometry: CD19, CD20(dim), CD5, CD23, sIg(dim), ZAP70
- FISH: trisomy 12, del(17p) and del(11q)
This is a fictional patient example
![Choose IMBRUVICA® first for patients like David[^1][^2] [^1]: Allan JN, <em>et al.</em> Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years follow-up in patients with <em>TP53</em> aberrations (del(17p) or <em>TP53</em> mutation): A pooled analysis from 4 clinical trials. Oral and Poster Abstracts presented at 62nd ASH Annual Meeting and Exposition; December 5-8 2020; all-virtual #2219. [^2]: Eichhorst B, <em>et al.</em> Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol.</em> 2021;32(1):23-33.](https://eu-images.contentstack.com/v3/assets/blt6b8ca7f1bf9e5733/blt884782257b74875d/636ba8b32d8c1537aef2b352/feature_banner_2.png?width=1920&height=360&format=webp&quality=50)
Choose IMBRUVICA® first for patients like David[1][2]
IMBRUVICA® is the only targeted therapy proven to have sustained long-term efficacy in high-risk patients with genetic aberrations[1][3]
Del(17p) is traditionally associated with poor prognosis in CLL[4][5]
Patients with del(17p) are more likely to have progression events on venetoclax + obinutuzumab or obinutuzumab + chlorambucil (N=432):[4]*
Chemoimmunotherapy is associated with a poor prognosis in patients with del(17p)[1]
Fludarabine, cyclophosphamide and rituximab (FCR) survival at 3 years in patients with del(17p) (n=51):[6]*
IMBRUVICA® has demonstrated sustained survival benefits in patients with del(17p) or TP53 mutation[1]
IMBRUVICA® survival at 4 years in patients with del(17p) or TP53 (n=89):[1]†
IMBRUVICA® is a preferred firstline treatment in patients with del(17p) CLL[2]
IMBRUVICA® is the only novel targeted therapy with a 97% reduction in risk of disease progression or death in patients with del(11q) at up to 7 years of follow-up[3]
IMBRUVICA® vs. chlorambucil PFS by del(11q) status at up to 7 years[3]
Adapted from Ghia P, et al. 2021.[3]
RESONATE-2 is a phase III, open-label, multicentre, international, randomised study investigating the long-term efficacy and safety of IMBRUVICA® vs. chlorambucil in patients with firstline CLL/SLL (up to 7 years of follow-up, N=269).[3]
CLL patient subgroups
uIGHV patients
Genetic aberration patients
Fit patients
Relapsed / refractory patients
Back to IMBRUVICA® studies
Back to IMBRUVICA® efficacy
*Vs. patients without del(17p).[4][6]
†In a cross-trial comparison of a pooled analysis across 4 clinical trials.[1]
BTKi=Bruton’s tyrosine kinase inhibitor; CI=confidence interval; Clb=chlorambucil; FCR=fludarabine + cyclophosphamide + rituximab; FISH=Fluorescence In Situ Hybridisation; HR=hazard ratio; OS=overall survival; PFS=progression-free survival.
CP-352641 - CP-352642 - October 2022
Johnson & Johnson Innovative Medicine NV